Emmaus Life Sciences, Inc.
EMMA
Price:
$0.03
Market Cap:
$1.92M
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus ...[Read more]
Industry
Biotechnology
IPO Date
2000-05-09
Stock Exchange
PNK
Ticker
EMMA
PE Ratio
[-0.43]
ROE
[10.80%]
Current Ratio
[0.14]
Dividend Yield
[0%]
Enterprise Value
[31.83M]
Dividend History
The ROE as of November 2024 (TTM) for Emmaus Life Sciences, Inc. (EMMA) is 10.80%
According to Emmaus Life Sciences, Inc.’s latest financial reports and current stock price. The company's current ROE is 10.80%. This represents a change of 368.37% compared to the average of 2.30% of the last 4 quarters.
Emmaus Life Sciences, Inc. (EMMA) Historical ROE (quarterly & annually)
How has EMMA ROE performed in the past?
The mean historical ROE of Emmaus Life Sciences, Inc. over the last ten years is 272.67%. The current 10.80% ROE has changed -96.04% with respect to the historical average. Over the past ten years (40 quarters), EMMA's ROE was at its highest in in the September 2016 quarter at 386.94%. The ROE was at its lowest in in the March 2017 quarter at -275.63%.
Average
272.67%
Median
50.61%
Minimum
-238.72%
Maximum
2.32%
Emmaus Life Sciences, Inc. (EMMA) ROE by Quarter and Year
Discovering the peaks and valleys of Emmaus Life Sciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.21%
Maximum Annual ROE = 2.32%
Minimum Annual Increase = -397.53%
Minimum Annual ROE = -238.72%
| Year | ROE | Change |
|---|---|---|
| 2023 | 7.82% | -75.06% |
| 2022 | 31.34% | -57.84% |
| 2021 | 74.34% | -397.53% |
| 2020 | -24.99% | -105.04% |
| 2019 | 496.17% | -307.85% |
| 2018 | -238.72% | 52.62% |
| 2017 | -156.41% | -106.75% |
| 2016 | 2.32% | 3.21% |
| 2015 | 69.87% | -53.77% |
| 2014 | 151.16% | -70.07% |
Emmaus Life Sciences, Inc. (EMMA) Average ROE
How has EMMA ROE performed in the past?
The current ROE of Emmaus Life Sciences, Inc. (EMMA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
37.83%
5-year avg
116.94%
10-year avg
272.67%
Emmaus Life Sciences, Inc. (EMMA) ROE vs. Peers
How is EMMA’s ROE compared to its peers?
Emmaus Life Sciences, Inc.’s ROE is less than NRx Pharmaceuticals, Inc. (193.11%), greater than Kaleido Biosciences, Inc. (0%), greater than Applied Molecular Transport Inc. (-218.56%), less than Scopus BioPharma Inc. (911.69%), less than Cell Source, Inc. (0%), less than Adhera Therapeutics, Inc. (31.36%), less than PolarityTE, Inc. (13.30%), less than ZIVO Bioscience, Inc. (84.08%), less than Anebulo Pharmaceuticals, Inc. (673.84%), greater than Adagene Inc. (-138.92%), greater than Acrivon Therapeutics, Inc. Common Stock (-50.10%), greater than AnaptysBio, Inc. (-47.31%), greater than Mineralys Therapeutics, Inc. (-255.67%), greater than null (-42.61%),
| Company | ROE | Market cap |
|---|---|---|
| 193.11% | $14.89M | |
| 0% | $4.26K | |
| -218.56% | $11.01M | |
| 911.69% | $16.83K | |
| 0% | $25.16M | |
| 31.36% | $1.44K | |
| 13.30% | $1.78M | |
| 84.08% | $68.83M | |
| 673.84% | $49.01M | |
| -138.92% | $135.03M | |
| -50.10% | $243.13M | |
| -47.31% | $602.18M | |
| -255.67% | $671.31M | |
| -42.61% | $0 |
Build a custom stock screener for Emmaus Life Sciences, Inc. (EMMA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Emmaus Life Sciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Emmaus Life Sciences, Inc. (EMMA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Emmaus Life Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Emmaus Life Sciences, Inc.'s ROE?
How is the ROE calculated for Emmaus Life Sciences, Inc. (EMMA)?
What is the highest ROE for Emmaus Life Sciences, Inc. (EMMA)?
What is the 3-year average ROE for Emmaus Life Sciences, Inc. (EMMA)?
What is the 5-year average ROE for Emmaus Life Sciences, Inc. (EMMA)?
How does the current ROE for Emmaus Life Sciences, Inc. (EMMA) compare to its historical average?